Blog

DEEP RESEARCH · CAREGEN

Caregen: Peptide Platform Upside and Commercial Execution Risk

A structured look at Korglutide, ProGsterol, and CG-P5 as extensions of Caregen’s peptide platform

Date: 2025-11-21 · biotech platform/pipeline analysis · Original Naver Blog post

Investment decisions are your own responsibility. This material is research, not a recommendation to buy or sell.

0. Bottom line first

My takeaway is that Caregen should be viewed less as a single-product biotech and more as a peptide application platform built around a library of more than 1,200 peptides, double-layered encapsulation delivery technology, and in-house synthesis capacity. The share-price relevance of that platform still depends on hard evidence: actual shipments of Korglutide and ProGsterol, CG-P5 clinical data, and more stable partnerships.

Official fact: The source says Caregen was founded in 2001, has focused on peptide R&D, holds a proprietary library of more than 1,200 peptides, and exports cosmeceutical products such as Dr. CYJ Hair Filler to over 130 countries.

Interpretation: I read Caregen as a peptide application platform that uses cosmeceutical cash flow to expand into nutraceuticals and pharmaceuticals, rather than as a conventional drug-development biotech alone.

Caregen platform expansion pathBased on technologies and product groups in the source
Library1,200+ peptides
DeliveryDouble-layered encapsulation
Commercial baseHair filler and cosmetics
Expansion optionsNutraceuticals and drugs
The platform’s value will be proven by approvals, shipments, and recurring revenue, not by technology claims alone

1. Core technology: double-layered encapsulation

Caregen’s technical edge is not just peptide synthesis; it is the attempt to deliver otherwise unstable peptides through skin, mucosa, and ocular tissue. The source describes capsules with an average size of about 140nm, with more than 80% of particles distributed below 100nm, as the basis for stability and penetration.

Stability

Nano-capsule protection

A liposome-like double membrane protects peptides from external conditions and enzymatic degradation.

Delivery

Skin and mucosal penetration

The source presents the technology as a basis for moving beyond the epidermis into the dermis.

Formulation

Multiple dosage forms

The same delivery logic supports cosmetics, oral formulations, and eye-drop pipelines such as CG-P5.

2. Korglutide: an oral obesity-management option

Official fact: The source reports that an India trial of Korglutide showed average body-weight reduction of 10.78% at 12 weeks (p<0.0001), fat-mass reduction of 12.12kg (-30.15%), and skeletal-muscle-mass reduction of only 1.25kg (-3.04%). It also says Korglutide has health-supplement approval in India and is awaiting the outcome of a U.S. NDI filing.

ItemKey source detailInvestment angle
RouteOral administrationMore convenient than injectable products
Weight change-10.78% over 12 weeks, p<0.0001Presented as strong data for a supplement-positioned product
Body compositionFat mass -12.12kg; skeletal muscle -1.25kgThe muscle-preservation narrative is the main differentiation point
CommercializationIndia supplement approval; U.S. NDI filingA faster-market-entry strategy than a full drug pathway

Interpretation: Korglutide is more interesting as an OTC or supplement-style niche for people avoiding injections, prescriptions, or long-term maintenance issues than as a direct head-to-head competitor to big-pharma GLP-1 drugs. The limit is that NDI status is not a drug approval and does not support disease-treatment marketing.

3. ProGsterol: NDI proof point and sales gap

ProGsterol, ingredient name Deglusterol, is a synthetic peptide for blood-glucose management. The source says it became the world’s first synthetic peptide to obtain FDA NDI status in March 2022. Its proposed mechanism centers on improving insulin resistance, protecting beta cells, and supporting natural glucose control.

CategorySource detail
Regulatory positionNDI dietary-ingredient status, not a drug approval
Global contractsAs of early 2023, roughly KRW 1tn in supply contracts across 11 countries was announced
Initial targetAbout KRW 100bn in 2023 sales
RealityAbout KRW 8.5bn in cumulative sales through 3Q 2023
Main causeCountry-level registration delays and slower partner marketing

Interpretation: ProGsterol is both a proof point for Caregen’s NDI strategy and a warning about execution. Announced contracts matter less than registrations, actual shipments, and repeat orders.

4. CG-P5: an eye-drop option for wet AMD

Official fact: CG-P5 is an eye-drop peptide pipeline for wet age-related macular degeneration. The source cites a U.S. Phase 1 study under ClinicalTrials.gov identifier NCT06132035, described as a randomized, parallel, placebo-controlled study assessing safety and tolerability.

CG-P5 clinical hypothesisSource thesis: reduce the burden of ocular injections with eye drops
Current standardAnti-VEGF intravitreal injections
Unmet needPain, infection risk, clinic visits
Caregen approachVEGFR2 and complement-system angle
Key proofRetinal delivery and efficacy data
If it works, convenience is meaningful; the hard problem is proving that an eye drop can deliver enough drug to the retina

5. Financials and risk: high margins, execution still unproven

Item2022 consolidated2023 consolidated2024 3Q status
RevenueAbout KRW 69.1bnKRW 79.2bn3Q revenue about KRW 17.1bn, YoY -15.9%
Operating profitAbout KRW 31.9bnKRW 40.3bn3Q operating profit about KRW 9.9bn, YoY -22.2%
Operating marginAbout 46%50.9%Expected to remain around the 50% level
Net incomeAbout KRW 28.0bnKRW 39.9bnNo separate source number shown
Positive

10-ton synthesis plant

The source frames in-house peptide synthesis capacity as the asset behind low cost and roughly 50% operating margins.

Risk

Contract credibility

The terminated German BeaStylez hair-filler supply contract of about KRW 57.3bn and the Curatis issue remain partnership risks.

Watch

Akums India partnership

The Akums Drugs and Pharmaceuticals partnership is presented as a positive signal for India commercialization.

6. Monitoring points

  1. Watch whether Korglutide’s U.S. NDI decision and India launch translate into actual revenue.
  2. Track whether CG-P5 Phase 1 data supports not only safety but also a credible drug-delivery path.
  3. Check whether ProGsterol and Korglutide export revenue appears in quarterly financials and whether unstable partnerships are resolved.

Interpretation: I view Caregen as a high-risk, high-return peptide platform with real technology but still-unproven commercial execution. A conservative investor would wait for NDI approval, clinical data, and shipment evidence.

Sources

Naver original